|
Re: Bioasis Announces Positive Results from NHP study w/ xB³-001
|
4
|
BIOASIS TECHNOLOGIES INC
|
Nov 21, 2018 10:29AM
|
|
Re: Bioasis Announces Positive Results from NHP study w/ xB³-001
|
2
|
BIOASIS TECHNOLOGIES INC
|
Nov 21, 2018 10:31AM
|
|
Re: Losing exclusivity on Aberatirone may not be all that bad for JNJ or ZEL
|
4
|
Zenith Epigenetics
|
Nov 22, 2018 05:53PM
|
|
Re: Bioasis Announces Positive Results from NHP study w/ xB³-001
|
5
|
BIOASIS TECHNOLOGIES INC
|
Nov 23, 2018 03:44PM
|
|
BET Inhibition Improves NASH and Liver Fibrosis
|
4
|
Resverlogix Corp.
|
Nov 24, 2018 11:30PM
|
|
Re: What is Mr. Market saying about RVX?
|
4
|
Resverlogix Corp.
|
Nov 25, 2018 01:28PM
|
|
Re: What is Mr. Market saying about RVX?
|
3
|
Resverlogix Corp.
|
Nov 26, 2018 11:25AM
|
|
Re: What is Mr. Market saying about RVX?
|
3
|
Resverlogix Corp.
|
Nov 26, 2018 03:56PM
|
|
2019 Potential Events
|
4
|
Resverlogix Corp.
|
Nov 27, 2018 12:02PM
|
|
Resverlogix Announces Publication on Apabetalone in Atherosclerosis Journal
|
4
|
Resverlogix Corp.
|
Nov 28, 2018 08:59AM
|
|
Re: Resverlogix Announces Publication on Apabetalone in Atherosclerosis Journal
|
8
|
Resverlogix Corp.
|
Nov 28, 2018 09:06AM
|
|
Re: Resverlogix Announces Publication on Apabetalone in Atherosclerosis Journal
|
4
|
Resverlogix Corp.
|
Nov 28, 2018 10:39AM
|
|
Re: Mace Events Study / Type 2 Diabetes / Control Arms 26 CVOT Trials
|
1
|
Resverlogix Corp.
|
Nov 29, 2018 10:38AM
|
|
Re: Mace Events Study / Type 2 Diabetes / Control Arms 26 CVOT Trials
|
3
|
Resverlogix Corp.
|
Nov 29, 2018 11:01AM
|
|
Re: Mace Events Study / Type 2 Diabetes / Control Arms 26 CVOT Trials
|
2
|
Resverlogix Corp.
|
Nov 29, 2018 11:49AM
|
|
Re: Pointing in the right direction & bogus Lilly
|
4
|
Resverlogix Corp.
|
Nov 30, 2018 09:02AM
|
|
Re: Tundup
|
1
|
Resverlogix Corp.
|
Nov 30, 2018 10:20AM
|
|
Re: Tundup
|
2
|
Resverlogix Corp.
|
Nov 30, 2018 01:44PM
|
|
Re: Can we end November with a bang?
|
3
|
Resverlogix Corp.
|
Nov 30, 2018 03:14PM
|
|
Re: The Pfizer connection...
|
4
|
Resverlogix Corp.
|
Dec 01, 2018 09:16AM
|
